Evidence map›Paper›PMID 42708599›Full record

ArticleMicrobiology spectrum2026

Validation of electrochemiluminescent (ECL)-based immunoassay to determine the levels of antibodies against

Maanan Kamdar, Vichiksha Shah, Sarah Janssen, Elizabeth Garcia Dominguez, Todd Davies, Germie van den Dobbelsteen

Abstract readValidation Study
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maanan KamdarBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.ORCID 0009-0008-1504-8257
Vichiksha ShahBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Sarah JanssenDiscovery and Manufacturing Statistics, Johnson & Johnson Innovative Medicine, Leiden, the Netherlands.
Elizabeth Garcia DominguezBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Todd DaviesBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Germie van den DobbelsteenBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Leiden, the Netherlands.ORCID 0009-0009-3703-9842

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extra-intestinal pathogenic IMPORTANCE: Extraintestinal pathogenic

Indexed as

Antibodies, BacterialEscherichia coliEscherichia coli InfectionsLuminescent MeasurementsO AntigensEnzyme-Linked Immunosorbent AssayHumansImmunoassayImmunoglobulin GSensitivity and SpecificityAntibodies, BacterialImmunoglobulin GO AntigensECL validationExPECO-antigenserum

Identifiers

PMID42708599
PMCPMC13689413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.